Low-Dose Sulphonylurea and DPP4 Inhibitor Combo lowers blood sugar by augmentating beta cell function
In the pursuit of refining diabetes treatment, a recent unblinded randomized crossover study explored the potential synergy between low-dose sulphonylureas (SU) and dipeptidyl peptidase-4 inhibitors (DPP4i). This combination aimed to augment the classical incretin effect and enhance glucose sensitivity in individuals with type 2 diabetes (T2DM). This study was published in The Journal Of Clinical Endocrinology And Metabolism by Cordiner and colleagues.
Low-dose sulphonylureas have demonstrated the ability to enhance the incretin effect and increase glucose sensitivity. The study aimed to evaluate whether combining low-dose sulphonylurea with a DPP4 inhibitor could produce an additive effect in improving glucose control.
Conducted at the Clinical Research Centre, University of Dundee, the unblinded randomized crossover study involved 30 participants with T2DM treated with diet or metformin. Fourteen-day intervention blocks included control, gliclazide 20 mg (SU), sitagliptin 100 mg (DPP4i), or the combination of both (SUDPP4i). The primary outcome was the effect of treatment on beta-cell glucose sensitivity.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.